Work

Supplementary Methods and Materials and Supplementary Figures 1-2 from Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Year: 2023

Type: supplementary-materials

Abstract: PDF - 278K, Supplementary Methods and Materials, QTc prolongation results. Supplementary Figure 1 - QTc prolongation compared with serum U3-1287 concentration. Supplementary Figure 2 - U3-1287-mediated pancreatic xenograft growth inhibition)

DOI: 10.1158/1078-0432.22451111

Authors: Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira, Naiyer Rizvi, Lisa Malburg, Vicki Keedy, Lorrin Yee, Catherine Copigneaux, Thore Hettmann, Chi-Yuan Wu, Agnes Ang, Abdel-Baset Halim, Robert A. Beckman, Darrin Beaupre, Jordan Berlin

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361883057

Cites:

Cited by:

Related to: 10